Prognostic Value of CD123 in Acute Myeloid Leukemia Patients with Intermediate Risk in Normal Karyotype.
10.19746/j.cnki.issn.1009-2137.2020.06.015
- Author:
Yu ZHANG
1
;
Ruo-Yang LIU
1
;
Shu-Juan WANG
1
;
Chong WANG
1
;
Qiu-Tang ZHANG
1
;
Chen HE
1
;
Xin-Sheng XIE
1
;
Ding-Ming WAN
1
;
Zhong-Xing JIANG
1
;
Yan-Fang LIU
2
,
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China.
2. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
3. E-mail: fccliuyf1@zzu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Interleukin-3 Receptor alpha Subunit;
Karyotype;
Leukemia, Myeloid, Acute/genetics*;
Mutation;
Patients;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(6):1880-1884
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression of CD123 in patients with acute myeloid leukemia (AML) and its relationship between clinical features, concomitant fusion gene or gene mutation, efficacy and prognosis.
METHODS:365 patients with newly diagnosed AML (except M3) treated in the First Affiliated Hospital of Zhengzhou University were enrolled and retrospective analysis, and multi-parameter flow cytometry was performed to detect the expression of CD123 in myeloid leukemia cell population. CD123≥20% was defined as positive. Clinical features, concomitant fusion gene or gene mutation, efficacy and prognosis of CD123
RESULTS:The positive rate of CD123 in 365 newly diagnosed AML patients was 38.9%. Compared with the CD123
CONCLUSION:CD123 positive indicates that AML patients have higher tumor burden and are more difficult to reach remission. It is an independent risk factor for OS and EFS in patients with normal karyotype and intermediate risk, which is important to evaluate the prognosis of patients with AML without specific prognostic marker.
